Monogram Technologies is a pre-revenue medical device startup developing the mBôs TKA System, an autonomous surgical robot for knee replacement procedures. Unlike existing robotic systems — most notably Stryker's Mako, which dominates the market — where the surgeon physically guides the robotic arm, Monogram's system is designed to autonomously execute pre-planned bone cuts using a robotic saw, guided by a CT scan of the patient's knee. The company has submitted a 510(k) application to the FDA and is awaiting a clearance decision. Monogram plans to operate a razor-razorblade business model: the robot is placed at hospitals (sold or subsidized in exchange for utilization commitments), while recurring revenue comes from per-procedure implant sales, single-use consumables, and annual software licenses. Implant revenue is the primary long-term profit driver, with knee implant components priced at roughly $4,278 per procedure. Monogram has licensed FDA-cleared total knee, partial knee, and total hip implant systems to support this model. The company's near-term focus is exclusively on total knee arthroplasty, with plans to expand the same robotic platform to hip, shoulder, and other joint applications over time. In parallel, Monogram is conducting a clinical trial in India through a partnership with Shalby, a large orthopedic hospital chain, to generate clinical data for the next-generation autonomous system. The company currently has no product revenue and burns roughly $1.1–1.2M per month.